<?xml version="1.0" encoding="UTF-8"?>
<p id="para170">For both treatment groups, dose modifications were required for treatment-related toxicities in accordance with the study protocol. Dose banding as per local guidelines was permitted. Administration of supportive medication, including antiemetic therapy, prophylaxis for tumour lysis, granulocyte-colony stimulating factor (G-CSF), prophylaxis for 
 <italic>Pneumocystis jirovecii</italic> pneumonia, fluid and electrolyte administration relating to cisplatin, and administration of prophylaxis for CNS relapse, was given in accordance with local practice.
</p>
